CN107530396B - 用于治疗眼科疾病的脂联素拟肽 - Google Patents

用于治疗眼科疾病的脂联素拟肽 Download PDF

Info

Publication number
CN107530396B
CN107530396B CN201680023972.XA CN201680023972A CN107530396B CN 107530396 B CN107530396 B CN 107530396B CN 201680023972 A CN201680023972 A CN 201680023972A CN 107530396 B CN107530396 B CN 107530396B
Authority
CN
China
Prior art keywords
xaa
dry eye
composition
acid
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680023972.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107530396A (zh
Inventor
H·许
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allysta Pharmaceuticals Inc
Original Assignee
Allysta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allysta Pharmaceuticals Inc filed Critical Allysta Pharmaceuticals Inc
Priority to CN202210970186.8A priority Critical patent/CN115919996A/zh
Publication of CN107530396A publication Critical patent/CN107530396A/zh
Application granted granted Critical
Publication of CN107530396B publication Critical patent/CN107530396B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
CN201680023972.XA 2015-05-01 2016-04-29 用于治疗眼科疾病的脂联素拟肽 Active CN107530396B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210970186.8A CN115919996A (zh) 2015-05-01 2016-04-29 用于治疗眼科疾病的脂联素拟肽

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562156127P 2015-05-01 2015-05-01
US62/156,127 2015-05-01
PCT/US2016/030142 WO2016179007A1 (en) 2015-05-01 2016-04-29 Adiponectin peptidomimetics for treating ocular disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210970186.8A Division CN115919996A (zh) 2015-05-01 2016-04-29 用于治疗眼科疾病的脂联素拟肽

Publications (2)

Publication Number Publication Date
CN107530396A CN107530396A (zh) 2018-01-02
CN107530396B true CN107530396B (zh) 2022-08-26

Family

ID=57218292

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201680023972.XA Active CN107530396B (zh) 2015-05-01 2016-04-29 用于治疗眼科疾病的脂联素拟肽
CN202210970186.8A Pending CN115919996A (zh) 2015-05-01 2016-04-29 用于治疗眼科疾病的脂联素拟肽
CN201880052451.6A Pending CN111032070A (zh) 2015-05-01 2018-08-07 用于治疗眼病的脂联素拟肽

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210970186.8A Pending CN115919996A (zh) 2015-05-01 2016-04-29 用于治疗眼科疾病的脂联素拟肽
CN201880052451.6A Pending CN111032070A (zh) 2015-05-01 2018-08-07 用于治疗眼病的脂联素拟肽

Country Status (12)

Country Link
US (6) US10987401B2 (enExample)
EP (3) EP3288577B1 (enExample)
JP (1) JP7245649B2 (enExample)
KR (2) KR20170141692A (enExample)
CN (3) CN107530396B (enExample)
AU (3) AU2016257724B2 (enExample)
CA (3) CA2981822C (enExample)
DK (1) DK3288577T3 (enExample)
ES (1) ES2903448T3 (enExample)
IL (1) IL272449A (enExample)
SG (1) SG11202001140UA (enExample)
WO (2) WO2016179007A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10987401B2 (en) 2015-05-01 2021-04-27 Allysta Pharmaceuticals, Inc. Adiponectin peptidomimetics for treating ocular disorders
CN110381920A (zh) * 2017-03-09 2019-10-25 雅利斯塔制药公司 用于干眼病的肽
CN107149676A (zh) * 2017-05-05 2017-09-12 杨硕 脂联素和脂联素/胰岛素混合液在改善及治疗眼表角膜上皮及神经损伤中的应用
WO2019061491A1 (en) * 2017-09-30 2019-04-04 Pro Sunfun Biotech Research And Development Co., Ltd. PEPTIDE FOR OCULAR CARE, COMPOSITION AND METHOD OF USE THEREOF
CN109912685B (zh) * 2017-12-13 2022-05-06 三凡生技研发股份有限公司 眼睛保护胜肽及其组合物及使用该胜肽的用途
EP3768296B1 (en) * 2018-03-23 2023-09-06 Arch Biosurgery, Inc. Sap and peptidomimetics for treatment of eye disease
EP3870204A4 (en) * 2018-10-24 2022-12-21 Allysta Pharmaceuticals, Inc. Adiponectin peptidomimetics formulations
JP7699426B2 (ja) * 2018-11-30 2025-06-27 ロート製薬株式会社 光線による障害からの細胞保護用眼科組成物
KR20220034199A (ko) 2019-09-18 2022-03-17 알콘 인코포레이티드 습식-패킹 소프트 하이드로겔 안구 삽입물
US11229549B2 (en) * 2019-09-18 2022-01-25 Vance M. Thompson Tear transplantation and multi-part contact lens with absorbent portion
US11213551B1 (en) 2021-04-05 2022-01-04 Korb Research, Llc. Ocular treatment compositions and methods of use thereof
KR20240108412A (ko) * 2021-10-20 2024-07-09 스텔스 바이오테라퓨틱스 인코포레이티드 안과 병태를 치료하거나, 예방하거나, 억제하거나, 경감하거나 발병을 지연시키기 위한 방법 및 펩타이드 모방체를 포함하는 조성물
WO2023069255A1 (en) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023107796A1 (en) * 2021-12-11 2023-06-15 The Regents Of The University Of California Ophthalmic formulations for macular degeneration
WO2024180472A1 (en) 2023-02-28 2024-09-06 Alcon Inc. Ocular inserts
KR102609115B1 (ko) * 2023-06-08 2023-12-05 주식회사 엔큐라젠 펩타이드를 포함하는 안구 질환의 치료용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE4437604A1 (de) 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
NZ507456A (en) 1998-04-28 2003-10-31 Applied Research Systems Process and conjugated forms of PEGylated interferon- beta with polyethylene glycol (PEG) wherein the thiol reactive polyol agent is mono-methoxylated
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
JP2005535561A (ja) 2002-01-18 2005-11-24 プロテミックス コーポレイション リミティド アディポネクチンのグリコアイソフォームとその使用
EA200900786A1 (ru) * 2005-04-29 2009-10-30 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Пептид в качестве лекарственного средства и способ лечения патологий, связанных с воспалительными процессами, посредством пептида
WO2012142142A2 (en) * 2011-04-12 2012-10-18 Temple University - Of The Commonwealth System Higher Education Adiponectin receptor agonists and methods of use
KR101438744B1 (ko) 2012-08-02 2014-09-15 전남대학교산학협력단 아디포넥틴을 유효성분으로 포함하는 안구건조증 또는 염증성 안구표면 질환의 예방 또는 치료용 조성물
CN104884006B (zh) * 2012-10-26 2017-12-15 弗赛特影像5股份有限公司 用于持续释放药物到眼睛的眼科系统
US10987401B2 (en) * 2015-05-01 2021-04-27 Allysta Pharmaceuticals, Inc. Adiponectin peptidomimetics for treating ocular disorders

Also Published As

Publication number Publication date
US20210128671A1 (en) 2021-05-06
CA2981822A1 (en) 2016-11-10
JP7245649B2 (ja) 2023-03-24
CA2981822C (en) 2023-04-11
US20230074446A1 (en) 2023-03-09
CN107530396A (zh) 2018-01-02
US10537608B2 (en) 2020-01-21
AU2016257724B2 (en) 2021-02-25
HK1246178A1 (zh) 2018-09-07
ES2903448T3 (es) 2022-04-01
EP3288577B1 (en) 2021-10-27
AU2021203254A1 (en) 2021-06-17
EP3668530A1 (en) 2020-06-24
EP4014985A1 (en) 2022-06-22
US10987401B2 (en) 2021-04-27
CA3191203A1 (en) 2016-11-10
SG11202001140UA (en) 2020-03-30
DK3288577T3 (da) 2022-01-10
WO2019036223A1 (en) 2019-02-21
AU2016257724A1 (en) 2017-10-12
US11464825B2 (en) 2022-10-11
IL272449A (en) 2020-03-31
CA3071670A1 (en) 2019-02-21
US20180161390A1 (en) 2018-06-14
EP3668530A4 (en) 2021-07-21
EP3288577A1 (en) 2018-03-07
EP3288577A4 (en) 2018-12-26
US20180078616A1 (en) 2018-03-22
US20220331393A1 (en) 2022-10-20
JP2018514592A (ja) 2018-06-07
CN111032070A (zh) 2020-04-17
KR20170141692A (ko) 2017-12-26
AU2018318008A1 (en) 2020-02-06
CN115919996A (zh) 2023-04-07
US11273197B2 (en) 2022-03-15
WO2016179007A1 (en) 2016-11-10
KR20200039749A (ko) 2020-04-16
US20200085907A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
CN107530396B (zh) 用于治疗眼科疾病的脂联素拟肽
US11524045B2 (en) Peptides for dry eye disease
US20250099533A1 (en) Adiponectin peptidomimetics formulations
HK1246178B (en) Adiponectin peptidomimetics for treating ocular disorders
HK40027227A (en) Adiponectin peptidomimetics for treating ocular disorders
JP2020535117A (ja) 眼疾患を治療するためのアディポネクチンペプチド模倣薬
HK40058825A (en) Adiponectin peptidomimetics formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1246178

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment